Background {#Sec1}
==========

Approximately 0.5% of all neonates (i.e., about 25,000 infants per year in Europe) are extremely low gestational age neonates (ELGANs), i.e. have a gestational age at birth (GA) \< 28 completed weeks. The vast majority of ELGANs requires supplemental oxygen in addition to positive pressure respiratory support and frequently experience intermittent hypoxemic and hyperoxemic episodes. Intermittent hypoxemic episodes are predominantly caused by recurrent apnea due to immature development of the respiratory neuronal network (recently reviewed \[[@CR1], [@CR2]\]) but also secondary to active exhalation during mechanical ventilation \[[@CR3]\]. Hyperoxemic episodes are usually a consequence of inappropriate adjustments of FiO~2~ (during routine manual control of FiO~2~ (RMC) but potentially also during closed-loop automated control of FiO~2~ (FiO~2~-C)).

Complications of prematurity associated with recurrent hypoxemic episodes {#Sec2}
-------------------------------------------------------------------------

### Retinopathy of prematurity (ROP) {#Sec3}

Observational data indicated that both, severe and prolonged hypoxemic episodes \[[@CR4]--[@CR6]\], and wide fluctuations in oxygen levels \[[@CR7]\], increase the risk of ROP. Whereas a better control of SpO~2~-levels was associated with a decreased risk of ROP \[[@CR8]\].

### Death and neurodevelopmental impairment (NDI) {#Sec4}

Observational studies (recently reviewed in \[[@CR9]\]) as well as SpO~2~ data recorded during the Canadian Oxygen Trial (COT \[[@CR10]\],) suggest that late deaths (i.e. deaths beyond 36 weeks postmenstrual age (PMA)) and NDI (both cognitive and particularly motor impairment) are linked to hypoxemic episodes, particularly those of more than 60s duration \[[@CR6]\].

### Necrotizing enterocolitis (NEC) {#Sec5}

The NeOProM (Neonatal Oxygen Prospective Meta-analysis) collaboration reported a lower rate of severe NEC (defined as NEC leading to abdominal surgery or death) in infants assigned to the higher SpO~2~ target range (91--95% compared to 85--89%) \[[@CR11]\], which was linked to a lower proportion of time spent with SpO~2~ \< 80%.

Complications of prematurity associated with hyperoxemic episodes {#Sec6}
-----------------------------------------------------------------

Considering that breathing room air (i.e., FiO~2~ = 0.21) leads to a relative hyperoxia compared to intrauterine oxygen partial pressures (PO~2~) and oxidative stress in preterm infants, hyperoxia, caused by inadequately high FiO~2~, is likely associated with long-term adverse effects \[[@CR12]\].

### ROP {#Sec7}

The causal relationship between prolonged inappropriate exposure to high oxygen concentrations and ROP has long been established \[[@CR13], [@CR14]\]. More recently, the NeOProM studies showed increased rates of ROP with the higher SpO~2~-target range (91--95%) \[[@CR11]\]. Finally, implementation of the higher SpO~2~-target range based on the results of the NeOProM studies, was associated with an increase in ROP rates in a recent observational study \[[@CR15]\].

### Death and NDI {#Sec8}

Data from experimental studies in rodents indicate that higher levels of oxygen (e.g., FiO~2~ 0.80 for 2 to 24 h \[[@CR16]--[@CR18]\]) trigger apoptotic neurodegeneration or white matter damage in the brain. These effects have been reviewed by Back et al. \[[@CR19]\].

### Chronic lung disease of prematurity (BPD) {#Sec9}

Hyperoxia enhancing generation of reactive oxygen species triggers inflammatory processes, tissue damage and cell death in the preterm infant's lung, eventually resulting in an increased risk of BPD development (recently reviewed in \[[@CR20]\]).

Controlling of FiO~2~ {#Sec10}
---------------------

To protect ELGANs from the detrimental effects of hypoxemic and hyperoxemic episodes, it can be assumed that PO~2~ (and in appropriate simplification SpO~2~) must be kept within a narrow target range. To achieve this goal despite the infants' irregular breathing patterns and variations in lung aeration and function, frequent cautious adjustments of FiO~2~ are required, which are challenging, time consuming and often impossible due to limited personnel resources.

It has repeatedly been shown that FiO~2~-C increases the time infants spent within the SpO~2~-target range and reduces the burden of hyper−/hypoxemia while being safe and accurate in short-term studies (reviewed in \[[@CR21], [@CR22]\]). The effects of FiO~2~-C on clinically relevant outcomes measures (such as the hypoxia and hyperoxia-associated complications of prematurity described above) and the safety of its long-term continuous application, however, have yet to be elucidated.

Methods/design {#Sec11}
==============

Trial objectives {#Sec12}
----------------

The proposed trial was designed and is powered to compare the effect of FiO~2~-C in addition to manual adjustments, in comparison with RMC of FiO~2~ only, on death, NDI and severe complications of prematurity thought to be related to hypoxia/hyperoxia in ELGANs.

Trial design {#Sec13}
------------

This is an outcome-assessor-blinded, randomized-controlled, multicenter parallel group comparison of phase III for superiority (evaluating FiO~2~-C in addition to RMC of FiO~2~ in comparison to RMC of FiO~2~ only) in ELGANs.

In Germany, this study is also considered as a phase IV pharmaceutical trial on safety of the investigational medication 'oxygen' using different modes of administration (decision of the German authority BfArM according to §4 para. 23,1 of the German Pharmaceutical Act). This may not apply to other countries.

Setting {#Sec14}
-------

Patients will be recruited in approximately 75 European tertiary care neonatal centers. Recruitment has started in Germany and is intended to expand to additional sites in other European countries, after appropriate approvals will have been obtained.

Patients {#Sec15}
--------

### Inclusion criteria {#Sec16}

GA at birth 23 + 0/7 to 27 + 6/7 weeks

### Exclusion criteria {#Sec17}

Decision not to provide full life support / decision for palliative care only before study entrySevere congenital abnormalities (particularly those affecting respiratory, cardiovascular or gastrointestinal function or long-term neuro-cognitive development, whereas patent ductus arteriosus, patent foramen ovale (PFO), and atrial septal defects type II (ASDII) are not considered a congenital anomaly in preterm infants)Postnatal age \> 48 hLack of parental consentLack of device enabling closed-loop automatic control of FiO~2~ before randomization

Randomization and allocation concealment {#Sec18}
----------------------------------------

Study participants are randomly assigned in a 1:1 ratio to FiO~2~-C in addition to RMC of FiO~2~ (test intervention) or RMC of FiO~2~ only (control intervention).

A web-based randomization tool provided by the Interdisciplinary Center of Clinical Studies at the University Medical Center of the Johannes Gutenberg University Mainz is being used in this study. This program enables bound (into the same treatment group) or free (into different treatment groups) randomization of multiples based on parental choice and the number of available devices enabling FiO~2~-C.

A minimization algorithm is applied to preferentially aim for an even distribution of treatment assignment in both GA strata (i.e. \< 26 weeks and ≥ 26 weeks; 1st priority) and both gender strata (2nd priority) within each center.

Blinding {#Sec19}
--------

This study is outcome-assessor-blinded, meaning that the personnel performing the ophthalmological examinations throughout the initial hospitalization as well as the personnel performing the neurocognitive evaluation at 24 months corrected age will be blinded to the infants' treatment group assignment. Blinding of doctors, nurses, and parents is not possible with this type of study interventions.

Study intervention {#Sec20}
------------------

FiO~2~-C is provided by commercially available and CE marked infant ventilators with a FiO~2~-C algorithm intended for use in preterm infants. The FiO~2~-C algorithm must have been tested in human infants and shown to increase the %-time spent in the assigned SpO~2~ target range or to reduce the time in hypoxemia or hyperoxemia or to reduce the incidence/duration of hypoxemic or hyperoxemic episodes.

Each FiO~2~-C algorithm should be applied in its "optimal mode" (with respect to potentially variable settings provided by the manufacturer such as: averaging time of SpO~2~-input, response/wait-time, etc.) based on either evidence in the literature or consensus of the users.

Manual adjustments are encouraged whenever automatic FiO~2~ settings seem sub-optimal. In case of FiO~2~/SpO~2~-oscillations brought about by FiO~2~-C, settings need to be adapted or FiO~2~-C has to be temporarily interrupted.

Whenever possible, every study center will use only one type of FiO~2~-C algorithm.

Infants in the control group are treated (whenever possible) with the same type of infant ventilator for respiratory support (FiO~2~-C turned off) and RMC of FiO~2~ is applied by bedside nurse and medical staff throughout the initial hospitalization.

Care is taken in both groups that all staff are informed about the relevance of intermittent hypoxemia and hyperoxemia and trained to execute prudent and careful RMC of FiO~2~. This training may include a standard operating procedure for RMC, where the speed of increase/decrease in FiO~2~ depends on the magnitude of deviation from the SpO~2~ target range as previously described \[[@CR23], [@CR24]\].

The intervention should start as soon as possible after randomization and within 48 h after birth. The scheduled end of the study intervention is any of the following (whichever comes first): deathdischarge home from hospitaltransfer to another hospital where FiO~2~-C is not available (whereas such transfer is discouraged)a PMA of 36 + 0/7 weeks*final* discontinuation of positive pressure respiratory support, which does not include limited periods without positive pressure support for weaning.*If the infant requires positive pressure respiratory support again for any reason, the infant should again be supported by FiO* ~*2*~ *-C (provided a device supporting FiO* ~*2*~ *-C is available) until (other) criteria for scheduled end of study intervention are met.*a PMA of \> 32 + 0/7 weeks provided the following two additional criteria of respiratory stability are both met:◦ A) FiO~2~ = 0.21 for ≥48 h (for this criterion limited time periods with higher FiO~2~ for rescue or for recovery of intermittent hypoxemia will not be considered)

and ◦ B) less than 5 intermittent hypoxemic episodes with an SpO~2~ \< 80% per 8 h shift.

*If criteria A) or B) are no longer met, the infant should again be supported by the FiO* ~*2*~ *-C device until (other) criteria for scheduled end of study intervention are met.* a PMA of \> 32 + 0/7 weeks if the infant has to be transferred to an intermediate care unit where FiO~2~-C is not available

*If the infant is re-admitted to intensive care, the infant should again be supported by FiO* ~*2*~ *-C (provided a device supporting FiO* ~*2*~ *-C is available) until (other) criteria for scheduled end of study intervention are met.*

After the end of the study intervention, all study participants will be treated according to the state of the art care and local standards without further requirements or restrictions.

Concomitant interventions and medication {#Sec21}
----------------------------------------

Any concomitant medication that is clinically considered necessary for the patient will be allowed within the study, except for the control group, where closed-loop automatic control of FiO~2~ or any other automatic control of airway pressure/respiratory support etc. based on SpO~2~ or other vital signals are not allowed.

SpO~2~ measurements to guide FiO~2~-C {#Sec22}
-------------------------------------

All FiO~2~-Controllers should be based on SpO~2~-data generated by the same pulse oximeter technology (Masimo). In general, pre-ductal SpO~2~-sensor placement is preferred to guide FiO~2~-C as long as echocardiography demonstrates a patent ductus arteriosus.

SpO~2~-targets and alarm settings {#Sec23}
---------------------------------

The SpO~2~-target range selected by a center for clinical routine has to fulfill the following criteria: Study centers need to have a written guideline on SpO~2~-target range to ensure that the same SpO~2~-target range is applied in both study groupsThe SpO~2~-target has to be within the range of 87--95% (may include 87% and/or 95%),Care has to be taken that the same SpO~2~-target ranges are applied in clinical routine and in both study groups

Documentation of the study intervention {#Sec24}
---------------------------------------

In both study groups, the type of respiratory support, the type of ventilator and the application of FiO~2~-C have to be documented daily during the intervention period on a treatment log.

Primary outcome {#Sec25}
---------------

The primary outcome measure is a composite of death, BPD or NEC assessed at 36 weeks PMA and severe ROP assessed when full vascularization of the retina is documented.

Definitions of components of the primary outcome {#Sec26}
------------------------------------------------

### Severe ROP {#Sec27}

Defined as any ROP stage 3 or higher, or acute posterior ROP, or any ROP in Zone 1, or any treatment for ROP. ROP will be diagnosed at routine ophthalmological examinations, beginning at a PMA of 32 weeks according to international recommendations and local standards until complete vascularization of the retina \[[@CR25]\]. The severity of ROP will be graded according to the international classification \[[@CR26]\].

### BPD {#Sec28}

Defined as requiring positive pressure support or supplemental oxygen at 36 weeks ±2 days PMA, including an oxygen reduction test for infants requiring less than 0.3 FiO~2~, representing 'moderate' or 'severe' BPD according to the National Institute of Child Health and Development consensus definition \[[@CR27]\].

### NEC {#Sec29}

Defined as modified Bell stage ≥IIa \[[@CR28]\] until 36 weeks PMA.

Co-primary outcome {#Sec30}
------------------

The co-primary outcome (tested in a hierarchical design) is the composite outcome of death, language or cognitive delay, motor impairment, severe visual impairment or hearing impairment, all assessed at 24 ± 1 months corrected age.

Definitions of components of the co-primary outcome {#Sec31}
---------------------------------------------------

*Language or Cognitive delay:* Defined as a language or cognitive composite score at the Bayley Scales of Infant Development 3rd edition \[[@CR29]\] of \< 85.

*Motor impairment:* Defined as a Gross Motor Function Classification System (GMFCS) score of 2--5 \[[@CR25]\].

*Severe visual impairment:* Defined as best corrected vision in the better eye yields a visual acuity less than 6/60 m (20/200 ft) according to the relevant doctor's reports / discharge summary.

*Severe hearing impairment:* need for a hearing aid or cochlear implant.

Any clinical suspicion of previously undiagnosed visual or hearing problems during the FiO~2~-C follow-up visit requires a referral to an eye specialist or an pedaudiologist.

*If the parents refuse the assessment at the study center or if Bayley test cannot be performed:*

Other assessments of neurocognitive and motor development will betaken into account, if parents refuse to attend the follow-up.

Cognitive- and language-composite-scores will then be imputed as follows:

A score "\> 85" will be imputed if a different cognitive test has been performed elsewhere and scored higher than 1SD below the meanthe family pediatrician/doctor/health professional caring for the child or the parents rate the infant as "normal"

A score "\< 85" will be imputed if a different cognitive test has been performed elsewhere and scored lower than 1SD below the meanthe family pediatrician/doctor/health professional caring for the child or the parents rate the infant as "delayed" or "impaired".

Any such imputation will be described in the final report and the scientific publication.

Secondary outcomes {#Sec32}
------------------

Key secondary outcome variables are the individual components of the primary (death, severe ROP, BPD, NEC) and co-primary outcome variables (death, cognitive delay or language delay, motor impairment (GMFCS score of 2--5 \[[@CR30]\]), as well as severe visual or hearing impairment,, the composite scores of the Bayley Scales (3rd edition), the rate of cerebral palsy (CP) according to the criteria defined by the European network 'Surveillance of CP in Europe', and the GMFCS score.

In addition to 'severe ROP' as component of the primary outcome, the 'ROP Severity Score' (also entitled 'ROP activity and structure score') \[[@CR31]\] is assessed as secondary outcome, enabling better differentiation and likely being more relevant for functional outcome.

Ethical considerations {#Sec33}
----------------------

The Helsinki Declaration shall be applied to the clinical trial, as well as Good Clinical Practice (GCP). The protocol was submitted and approved by the Ethics Committee of the University Hospital Tübingen as the lead ethics committee. Furthermore, the relevant ethics committees responsible for any of the participating study sites will have to approve participation of the site.

Community engagement {#Sec34}
--------------------

A freely accessible web page for *FiO*~*2*~*-C* has been set up ([www.fioc-study.eu](http://www.fioc-study.eu)), providing an overview of aims, partners, study outline, progress and milestones, meetings, findings and news.

Form of consent {#Sec35}
---------------

Written informed consent from parents or legal guardians is required for participation in the study.

Insurance {#Sec36}
---------

Where required by national law, insurance will be obtained for all study patients.

Sample size, power and study duration {#Sec37}
-------------------------------------

The required sample size was calculated for the primary research hypothesis that the implementation of FiO~2~-C reduces the cumulative incidence of the composite primary outcome (death, severe ROP, BPD, or NEC).

The co-primary research hypothesis is that FiO~2~-C also reduces death or severe NDI (see outcome measures for details). These hypotheses are assessed as a-priori ordered hypotheses, where the co-primary hypothesis will only be tested in a confirmatory manner if the primary hypothesis has been confirmed. Consequently, no correction for multiple testing will be performed.

We assume that, the cumulative incidence of the primary composite outcome of this study is 50% in the control groupFiO~2~-C reduces the burden of severe hypoxemia/hyperoxemia by 25--50% and (based on the assumption that (again) 25--50% of the outcome is associated with recurrent hypo−/hyperoxemia) effects a relative risk reduction in this outcome by at least 12.5%.

In summary, we assume a reduction in the primary outcome from 50% (in the control group) to 44% in the intervention group (FiO~2~-C).

Sample size calculations were based on a Χ^2^-test, assuming a power of 80% and a significance level of 5%. Based on these assumptions, 1110 infants are required in each treatment group (total 2220 infants). Because all components of this primary outcome will be determined during the initial hospitalization (i.e. until first discharge from neonatal care), the rate of drop-out before ascertainment of the primary outcome will be low as \< 5%. Hence, a total of 2340 infants need to be enrolled and randomized (see Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Anticipated Trial Flow

Assuming an incidence of 50% for the co-primary outcome in the control group and a relative risk reduction (RRR) of 25% for the co-primary outcome in the FiO~2~-C group, the proposed sample size will have a power \> 80% to prove this difference even if up to 20% of randomized infants will be lost to follow-up until 24 months corrected age.

It is estimated that about 90% of all ELGANs will qualify for inclusion into this study without any exclusion criteria. Estimating a participation rate of 80%, approximately 3350 infants have to be screened.

We estimate a recruitment of about 65 patients per month and therefore the recruitment phase of the study will last for approximately 36 months. The individual participation in the study will be about 27 months (between 56 and 91 days of treatment -- depending on GA at birth - with an additional follow up to 24 months corrected age).

Data analysis {#Sec38}
-------------

Analysis of the primary outcome will be based on the intention to treat analysis set, which comprises all randomized patients. Portions of infants with primary endpoint will be compared in a statistical model that accounts for the factors considered by the randomization procedure and the randomization of twins and other multiples. The treatment effect will be reported as a risk ratio and as a risk difference with 95% confidence interval. The co-primary outcome will be assessed only if superiority of FiO~2~-C with respect to the primary outcome is confirmed at the 2-sided level of 0.05. This hierarchical testing procedure maintains a multiple type I error of 0.05. All statistical analyses will be described in detail in a statistical analysis plan completed before closure of the database. An interim analysis for efficacy is not intended.

Monitoring safety {#Sec39}
-----------------

An independent Data Monitoring Committee (DMC) is instituted and monitors recruitment, compliance, and safety parameters after 50, 100, 200 and 300 patients have completed 44 + 0/7 weeks PMA, and after every 200 patients have reached this age thereafter.

Safety parameters {#Sec40}
-----------------

Safety parameters monitored by the DMC include:

Early deaths (for the DMC defined as \< 44 weeks PMA), late deaths (for the DMC defined as ≥44 weeks PMA), all deaths, BPD, discharge on home oxygen or home positive pressure respiratory support, severe ROP, NEC, (focal) intestinal perforation requiring laparotomy, PDA requiring treatment, intraventricular hemorrhage \>grade 2, cystic periventricular leukomalacia. Because the safety parameters include components of the primary outcome, the incidence rates and 95% confidence intervals, these parameters will be 'coded' as "safety parameter A-I".

Furthermore, safety analyses include occurrence and rates of reported adverse events and incidents by treatment group.

Regulatory aspects {#Sec41}
------------------

### Trial sponsor {#Sec42}

Sponsor of the FiO~2~-C-trial is the University Hospital Tübingen, Geissweg 3, 72,076 Tübingen, Germany. Contact is available at fioc\@med.uni-tuebingen.de.

### Medical ethics committees {#Sec43}

At the time of submission, the relevant ethics committee in Germany approved the study. Applications for approvals are currently underway in additional countries (e.g., the Netherlands and Switzerland).

### National Regulatory/competent authorities {#Sec44}

At the time of submission, the National Regulatory/Competent Authority of Germany (BfArM) approved the study. Authority approval may not be necessary elsewhere -- but this will be determined in collaboration with the relevant ethics committees.

Discussion {#Sec45}
==========

Need for a trial {#Sec46}
----------------

Oxygen is one of the drugs most frequently used in ELGANs and yet, our knowledge on the optimal level of oxygen in arterial blood (or in appropriate simplification the optimal target range for SpO~2~) and even optimal technology for monitoring oxygen levels is incomplete \[[@CR32]--[@CR34]\]. Short-term studies in preterm infants demonstrated that FiO~2~-C improved the time within the assigned SpO~2~ target range. In these studies, percent time within the assigned SpO~2~ target range increased by approximately 10% points to around 70--90% and the improvement was independent of the SpO~2~ target range, the FiO~2~-C algorithm, and the proportion of time spent within SpO~2~ target range in the control-group \[[@CR21], [@CR22], [@CR35], [@CR36]\]. It is, however, unclear if more time spent within the assigned SpO~2~ target range will also translate into positive long-lasting effects on clinically relevant outcomes. For example, despite higher proportions of time spent within the SpO~2~ target range, FiO~2~-C might on the one hand side reduce the amplitude of SpO~2~ fluctuations, but, at the same time increase the frequency of SpO~2~ oscillations and thereby might carry additional risks. This randomized controlled trial will ensure an appropriate assessment of safety and efficacy of FiO~2~-C, before it is implemented into standard care.

Discussion of the study intervention period {#Sec47}
-------------------------------------------

The study intervention period was chosen because Di Fiore et al. showed that hypoxemic episodes evolve over the first 2 weeks of life and hence starting the intervention within 48 h after birth seems appropriate. This will enable a reasonable time frame to inform parents, even if birth of the infant occurs at night or on weekends, and to enable a meaningful parental decision on participation.

As described by Di Fiore et al. \[[@CR5]\] and confirmed by Poets et al. \[[@CR6]\], hypoxemic episodes occurring beyond the 4th week of life are more strongly associated with adverse long-term outcomes than hypoxemic episodes occurring within the first 4 weeks of life. Hence, the study intervention should not end at 32 weeks PMA. Infants with prolonged and frequent hypoxemic episodes beyond this age may benefit most from effective FiO~2~-C.

Discussion of chosen population {#Sec48}
-------------------------------

Because diseases thought to be related to inappropriate use of oxygen such as ROP and BPD essentially only occur in ELGANs, an assessment of efficacy and safety of long-term application of FiO~2~-C can only be performed in this patient population.

Discussion of chosen SpO~2~-target range {#Sec49}
----------------------------------------

The NeOProM collaboration has shown that the higher SpO~2~-target range of 91 to 95% is associated with a decreased risk of early deaths at 18 to 24 months corrected age and NEC, but with an increased risk of ROP \[[@CR11]\]. Furthermore, a post-hoc analysis of the BOOST-II data indicated that a higher proportion of time within the assigned target range could enhance this beneficial effect \[[@CR37]\]. Consequently, in the FiO~2~-C trial the lower limit of the center-specific SpO~2~ target range has to be set to ≥87% SpO~2~.

Trial status {#Sec50}
============

Protocol version 4: April, 26th, 2018. Recruitment has started in July 2018 and is expected to be finalized in July 2021. The last patient out (after follow-up) will be expected in October 2023.
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